• Home
• com.imsweb
• staging-client-java
• 3.3
• source code
• ssf3_lpt.json

×

Project download

Many resources are needed to download a project. Please understand that we have to compensate our server costs. Thank you in advance.
Project price only 1 $

You can buy this project and download/modify it how often you want.

algorithms.cs.02.05.50.tables.ssf3_lpt.json Maven / Gradle / Ivy

{
  "id" : "ssf3_lpt",
  "algorithm" : "cs",
  "version" : "02.05.50",
  "name" : "SSF3",
  "title" : "CS Site-Specific Factor 3",
  "subtitle" : "Residual Tumor Status and Size After Primary Cytoreduction Surgery",
  "notes" : "**Note 1**:  The surgery to remove as much cancer in the pelvis and/or abdomen as possible, reducing the \"bulk\" of the cancer, is called \"debulking\" or \"cytoreductive\" surgery. It is performed when there is widespread evidence of advanced stage of ovarian cancer with obvious spread to other organs outside the ovary, typically in the upper abdomen, intestines, the omentum (the fat pad suspended from the transverse colon like an apron), the diaphragm, or liver. \n\n**Note 2**:  Optimal debulking is described as removal of all tumor except for residual nodules that measure no more than 1centimeter (cm) in maximum diameter.\n\n**Note 3**:  According to the AJCC, \"In advanced disease, the most important prognostic factor is the residual disease after the initial surgical management.\"  Neoadjuvant chemotherapy may be given to obtain optimum cytoreduction with less aggressive surgery; Recording whether the patient received chemotherapy prior to this procedure provides necessary data for treatment and survival analysis. \n\n**Note 4**:  Record the largest residual tumor nodule(s) remaining after primary cytoreductive surgery, as described by the surgeon in the operative report.",
  "last_modified" : "2015-05-27T16:20:06.070Z",
  "definition" : [ {
    "key" : "ssf3",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  } ],
  "rows" : [ [ "000", "No gross residual tumor nodules" ], [ "010", "Residual tumor nodule(s) 1 centimeter (cm) or less\nAND neoadjuvant chemotherapy not given or unknown if given" ], [ "020", "Residual tumor nodule(s) 1 cm or less\nAND neoadjuvant chemotherapy given (before surgery)" ], [ "030", "Residual tumor nodule(s) greater than 1 cm\nAND neoadjuvant chemotherapy not given or unknown if given" ], [ "040", "Residual tumor nodule(s) greater than 1 cm\nAND neoadjuvant chemotherapy given (before surgery)" ], [ "888", "OBSOLETE DATA CONVERTED V0200\nSee code 988 \n\nNot applicable for this site" ], [ "988", "Not applicable:  Information not collected for this case\n(May include cases converted from code 888 used in CSv1 for \"Not applicable\" or when the item was not collected.  If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)" ], [ "990", "Macroscopic residual tumor, size not stated\nAND neoadjuvant chemotherapy not given or unknown if given" ], [ "991", "Macroscopic residual tumor nodule(s), size not stated\nAND neoadjuvantchemotherapy given (before surgery)" ], [ "992", "Procedure described as optimal debulking and size of residual tumor nodule(s) not given \nAND neoadjuvant chemotherapy not given or unknown if given" ], [ "993", "Procedure described as optimal debulking and size of residual tumor nodule(s) not given \nAND neoadjuvant chemotherapy given (before surgery)" ], [ "998", "No cytoreductive surgery performed" ], [ "999", "Unknown or no information\nNot documented in patient record" ] ]
}